XBiotech Inc. (XBIT): Revenue Growth QoQ

XBIT (XBiotech USA) - company brandmark

XBiotech Inc. possesses a strong reputation for developing human antibodies that effectively suppress tumor growth. The quarterly sales growth illustrates the financial dynamics, where the value 0.00 represents the current metric. The company's prospects are tied to the development of Natrunix and partnerships with pharmaceutical behemoths, while the platform's patent protection creates a significant barrier to entry for new competitors.

XBiotech USA (XBIT) - Sales Change QoQ from 07/04/2022 to 11/20/2026

XBIT (XBiotech USA): analytical breakdowns and indicator data

- stock price and consensus target price:
- stock exchange capitalization data:
General company analysis:XBiotech USA - XBIT
Manufactured products of XBiotech Inc

XBiotech Inc. is developing advanced human monoclonal antibody synthesis technologies, strengthening oncologist confidence through the targeted blocking of tumor mechanisms. By analyzing quarterly sales revenue growth, an investor assesses the pace of revenue expansion, where excessive acceleration in the absence of fundamental support signals a decrease in the business model's margin of safety and increased risks to capital.

Competing companies

BeiGene Oncology - Quarterly Revenue Growth|HALO: Revenue Growth QoQ|Revolution Medicines Corp (RVMD) - Revenue Growth QoQ|Quarterly Revenue Growth Rate Ascentage Pharma Group International (AAPG)|Revenue Growth QoQ CG Oncology, Inc.|Quarterly Revenue Growth Rate UroGen Pharma Corp URGN|Quarterly Revenue Growth BCAX|Personalis, Inc. - Sales Growth QoQ|Erasca - Quarterly Sales Growth|Quarterly Revenue Increase DCTH|YMAB: Quarterly Sales Growth|Quarterly Revenue Growth Rate Aura Corp|CADL: Quarterly Revenue Growth|ARAY - Quarterly Sales Growth Rate|SLS (SELLAS Life Sciences Group, Inc.) - Quarterly Revenue Growth|ACTU: Quarterly Revenue Increase|Revenue Growth QoQ citiusonc.com (CTOR)|Quarterly Sales Growth Rate TuHURA Biosciences|Revenue Growth QoQ Protara Therapeutics TARA|Fate Therapeutics (FATE) - Quarterly Revenue Growth Rate|WHWK - Revenue Growth QoQ|Quarterly Revenue Growth Rate TScan Therapeutics Inc|championsoncology.com (CSBR) - Revenue Growth QoQ|CEL-SCI Corporation (CVM) - Quarterly Revenue Growth|Revenue Growth QoQ OS Therapies|RADX: Quarterly Revenue Increase|Revenue Growth QoQ artivabio.com (ARTV)|Quarterly Sales Growth Rate Adlai Nortye|Quarterly Revenue Growth VERU (Veru Corporation)|Sales Change QoQ TPST (Tempest Tx)|XLO: Quarterly Sales Growth|renovarobio.com (RENB) - Quarterly Sales Growth|Mural Bio (MURA) - Revenue Growth QoQ|Kairos Pharma Inc (KAPA) - Quarterly Revenue Growth|Quarterly Sales Growth OKUR|CytoMed Therapeutics (GDTC) - Quarterly Sales Growth Rate|Quarterly Sales Growth CRIS (Curis Inc.)|Quarterly Revenue Growth Apollomics Inc. (APLM)|Revenue Growth QoQ Tharimmune Corp THAR|Advanced Biomed Corp - Revenue Growth QoQ|GNPX: Quarterly Sales Growth|Calidi Biotherapeutics, Inc. (CLDI) - Quarterly Sales Growth|SBFM: Quarterly Revenue Growth|Quarterly Sales Growth Xenetic Biosciences Inc.|Revenue Growth QoQ Salarius Pharmaceuticals Inc|PPBT: Quarterly Revenue Increase|Quarterly Revenue Growth AONC|BGNE (BeOne Medicines) - Quarterly Revenue Increase|Checkpoint Therapeutics, Inc - Quarterly Sales Growth|elevationoncology.com (ELEV) - Quarterly Revenue Growth Rate|iCAD Inc. - Quarterly Revenue Growth|Quarterly Revenue Growth Rate Ikena Oncology|NTBL: Quarterly Revenue Growth|Quarterly Revenue Growth Rate Viracta (VIRX)|MOR (MorphoSys AG) - Quarterly Revenue Growth|NAYA: Quarterly Revenue Increase|Revenue Growth QoQ Ascentage Pharma Group Ltd (AAPGV)